Untitled

Yıldız, Esra; Oztan, Asli; Sar, Funda; Pınarbaşı, Ergün; Cetin-Atalay, Rengül; Akkız, Hikmet; Öztürk, Mehmet

doi:10.1023/a:1020161818764

Cited by 15 publications

(4 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Genotype determination rates vary by sample handling procedure and analysis method. According to the results of many other studies, genotype 1b is the most prevalent (66%-100%) HCV genotype in Turkey, and our findings are compatible with these results (3)(4)(5)(14)(15)(16)(17)(18)(19)(20). In a comprehensive survey, 87.2% of the patients had genotype 1b, 9.9% had genotype 1a, 0.9% had genotype 2, 1.4% had genotype 3, and 0.6% had genotype 4 (18).…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

Distribution of viral genotypes and extrahepatic manifestations inpatients with chronic hepatitis C in Eastern Turkey

Yılmaz¹,

Erol²,

Özbek³

et al. 2015

Turk J Med Sci

View full text Add to dashboard Cite

Background/aim: To investigate the distribution of viral genotypes, the extrahepatic manifestations, and the relationship between genotypes and extrahepatic manifestations in patients with chronic hepatitis C. Materials and methods:The study included 62 treatment-naive patients with chronic hepatitis C infection. Genotype determination was performed by DNA sequencing analysis. To investigate extrahepatic manifestations, the patients' data, recorded prospectively during the pretreatment period, were analyzed.Results: Genotype determination was successful in 74.2% of the cases. All patients were infected with hepatitis C virus (HCV) genotype 1b. At least 1 extrahepatic manifestation was identified in 37.1% of the patients. The most frequent clinical manifestations were type II diabetes mellitus (8.1%) and arthralgia or arthritis (8.0%). There was no relationship between extrahepatic manifestations and fibrosis or transaminase levels, but female sex and advanced age were risk factors. Because all patients were infected with the same genotype, the relationship between extrahepatic manifestations and genotype could not be examined. Conclusion:HCV genotype 1b is predominant in patients with chronic hepatitis C in the Eastern Anatolian Region of Turkey. In total, 37.1% of the patients had at least 1 extrahepatic manifestation. Female sex and advanced age were risk factors for having extrahepatic manifestations.

show abstract

Section: Discussionsupporting

confidence: 92%

“…Types 5 and 6 are largely confined to South Africa and South East Asia (2). In Turkey, the predominant genotype is 1b (66.7%-100%) (3)(4)(5).…”

Section: Introductionmentioning

confidence: 99%

Distribution of viral genotypes and extrahepatic manifestations inpatients with chronic hepatitis C in Eastern Turkey

Yılmaz¹,

Erol²,

Özbek³

et al. 2015

Turk J Med Sci

View full text Add to dashboard Cite

show abstract

“…The majority of IDUs harboured the genotypes 1a (60.8%), 3a (25.6%), while other chronically HCV mono-infected patients at the Pasteur Institute of Morocco in Casablanca primarily exhibited genotypes 1b and 2a/2c respectively (Table 1). A similar IDU profile has been documented in anti-HCV-positive subjects in other countries, some of which are in direct contact with Morocco and hugging the Mediterranean basin, such as Spain, Turkey, Croatia, and France (Payan et al; Yildiz et al; Vince et al; Lopez-Labrador et al) [17,21,34,35]. The Moroccan IDU profile does not match with neighbouring country Algeria or central Africa, which exhibit 1b, 2a/2c, and 4 as the predominant genotypes respectively (Rouabhia et al; Xu et al) [36,37], however we note that these cited studies were carried out in chronically infected and hemodialysis patients.…”

Section: Discussionsupporting

confidence: 64%

The “hidden” epidemic: a snapshot of Moroccan intravenous drug users

Trimbitas

Serghini²,

Lazaar

et al. 2014

Virol J

View full text Add to dashboard Cite

BackgroundHepatitis C virus is a persistent epidemiological problem, with an estimated 170 million individuals infected worldwide, and the leading cause of asymptomatic chronic infection, liver cirrhosis and hepatocellular carcinoma. Injection drug users (IDUs) have the highest seroprevalence as compared to chronic hemodialysis and transfusion patients, and this cohort remains the most under-studied high-risk group in North Africa to date. This study first sought to characterize the demographic, epidemiological, and genotypic profile of a total sample size of 211 chronically-infected IDUs living in the Tangier region of Northern Morocco, and secondly to contrast this to other chronically-infected patients, in order to uncover possible discrepancies.ResultsThe general ‘profile’ of local IDUs marks a stark contrast to chronically-infected HCV Moroccan patients, other African countries, and neighboring European countries. The majority of Moroccan drug users were found to be middle-aged and celibate. A relatively high seroprevalence was found among drug users (60%), and this increased with age. The majority of drug users shared their needles and this hold implications for transmission, as seropositive status was significantly different between those users that shared vs. those that did not share their needles. In addition, IDUs exhibited genotypes 1a and 3a predominantly, as compared to the predominant 1b and 2a/2c genotypes found in chronically HCV-infected patients. The IDU genotypic profile closely matches the one in other European countries (Portugal, Spain, France, and Italy), which are invariably speculated as the potential source of currently-circulating genotypes in Moroccan IDUs.ConclusionThese findings have implications for disease prevention, transmission and treatment, as this distinct IDU subgroup cannot be collectively pooled along with other HCV-positive high-risk groups. Local government, practitioners, and health institutions should take this into account when treating, prescribing antiviral therapy, and designing preventative public health campaigns.

show abstract

“…Moleküler çalışmalar ile dünya genelinde HCV genotiplerinin dağılımı ve bazı genotiplerin farklı bölgelerde daha baskın olduğu ortaya konmuştur (11,13) . Tüm dünyada sık olarak görülen HCV genotipleri, genotip 1, 2 ve 3 iken (1) , Türkiye'de yapılan çalışmalar-da da en baskın genotipin 1b olduğu ve bunu % 5.8-33.3 oranında genotip 1a'nın izlediği saptanmıştır (1,19) . Gürbüz ve ark.…”

Section: Discussionunclassified